- Home
- INBK vs CHRS Comparison
INBK vs CHRS Comparison
Compare INBK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- CHRS
- Stock Information
- Founded
- INBK 1999
- CHRS 2010
- Country
- INBK United States
- CHRS United States
- Employees
- INBK N/A
- CHRS N/A
- Industry
- INBK Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBK Finance
- CHRS Health Care
- Exchange
- INBK Nasdaq
- CHRS Nasdaq
- Market Cap
- INBK 191.0M
- CHRS 159.2M
- IPO Year
- INBK N/A
- CHRS 2014
- Fundamental
- Price
- INBK $24.10
- CHRS $1.35
- Analyst Decision
- INBK Hold
- CHRS Strong Buy
- Analyst Count
- INBK 3
- CHRS 4
- Target Price
- INBK $30.67
- CHRS $4.51
- AVG Volume (30 Days)
- INBK 32.6K
- CHRS 1.2M
- Earning Date
- INBK 10-22-2025
- CHRS 11-05-2025
- Dividend Yield
- INBK 1.01%
- CHRS N/A
- EPS Growth
- INBK N/A
- CHRS N/A
- EPS
- INBK 1.76
- CHRS 1.55
- Revenue
- INBK $106,219,000.00
- CHRS $272,209,000.00
- Revenue This Year
- INBK $5.27
- CHRS N/A
- Revenue Next Year
- INBK $27.40
- CHRS $109.48
- P/E Ratio
- INBK $13.56
- CHRS $0.87
- Revenue Growth
- INBK 4.74
- CHRS 52.33
- 52 Week Low
- INBK $19.54
- CHRS $0.66
- 52 Week High
- INBK $43.27
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- INBK 48.34
- CHRS 64.99
- Support Level
- INBK $23.52
- CHRS $1.23
- Resistance Level
- INBK $24.67
- CHRS $1.40
- Average True Range (ATR)
- INBK 0.77
- CHRS 0.08
- MACD
- INBK -0.07
- CHRS -0.00
- Stochastic Oscillator
- INBK 30.47
- CHRS 72.13
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.